Lyell Immunopharma, Inc. Common Stock(LYEL)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
LYEL
$14.05
—
Snapshot
$14.05
- 52-Week Range
- $9.03 – $45.00
- YTD
- -51.52%
- IV Rank (30D)
- 100
- Straddle Price
- $3.45
- P/C Vol Ratio
- 0.41
- Market Cap
- $0.3B
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.44% |
| Beta vs SPY | 1.31 |
| Cost of Equity (CAPM) | 11.67% (VRP-adj) |
| WACC | 10.31% |
| Volatility Risk Premium | +180.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -90.0% |
| Book / Price | 108.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -433609.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $16.51 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.85 |
| Bollinger Width / SMA20 | 159.5% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: BIIB, MRNA, REGN
(filtered from 8 ETF-co-members; sector bias active)
Model Conviction
92%
20-Day Fair Value
$15.43
α +9.8%
rank 82%
40-Day Fair Value
$15.04
α +7.1%
rank 71%
60-Day Fair Value
$16.89
α +20.2%
rank 81%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $31.61 | 17% | median 2.1× · 3 peers |
| Peer P/S | $0.01 | 17% | median 4.4× · 3 peers |
| Market Anchor (SMA50) | $16.51 | 65% | stability 73% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-07-03 · updated 2026-07-03 18:03:29.839000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.3B
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-tar…
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -13.61% | 5 |
| Feb | +14.93% | 5 |
| Mar | -17.52% | 5 |
| Apr | -5.92% | 5 |
| May | +8.69% | 5 |
| Jun | -2.40% | 6 |
| Jul | +2.39% | 6 |
| Aug | -2.91% | 5 |
| Sep | +1.36% | 5 |
| Oct | -8.06% | 5 |
| Nov | -3.75% | 5 |
| Dec | -6.31% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.85
SMA 50: $16.51
SMA 200: $20.77
Current: $14.05
EMA 12: $13.11
EMA 26: $13.99
MACD: -0.8819 | Signal: 0.3703
BEARISH
ADX (14): 30.53
TREND
+DI: 16.73
−DI: 18.23
Momentum Oscillators
RSI (14): 49.89
NEUTRAL
Stoch %K: 77.32
Stoch %D: 62.80
Williams %R: -6.01
Volume & Volatility
BB Upper: $14.16
BB Lower: $11.53
NEUTRAL
OBV: -2,346,606
Vol SMA 20: 241,873
Vol ROC: 31.33%
ATR: $1.31
True Range: $1.54
HV 20: 99.8%
HV 30: 107.8%
HV 60: 89.2%
Data Summary
Data Points: 500
Last Updated: 2026-07-02T21:15:16.436000
Date Range: 2024-07-05T00:00:00 – 2026-07-02T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
7 of 7 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-07 | After-Close | 441.49% | 6.38% | 0.01x | Within |
| 2024-11-07 | Pre-Market | 104.73% | 14.86% | 0.14x | Within |
| 2025-03-11 | Pre-Market | 157.28% | 6.04% | 0.04x | Within |
| 2025-05-13 | Pre-Market | 29.54% | 1.24% | 0.04x | Within |
| 2025-08-12 | Pre-Market | 9.22% | 1.89% | 0.20x | Within |
| 2025-11-12 | Pre-Market | 28.70% | 2.20% | 0.08x | Within |
| 2026-03-12 | After-Close | 19.95% | 13.16% | 0.66x | Within |
Options Activity
- IV Rank (30D)
- 100
- IV Rank (7D)
- 100
- Avg IV
- 288.0%
- Straddle (30D)
- $3.45
- Straddle (7D)
- $3.45
- P/C Volume
- 0.41
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 2.00
- Correlation (SPY)
- 29.9%
- R²
- 0.09
- Ann. Volatility
- 83.9%
- SPY Volatility
- 12.6%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 18,007,500 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$260.78K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $240.72K | 92.31% | 2026-03-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $20.06K | 7.69% | 2026-03-31 |
4 filers$191.35K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | DIADEMA PARTNERS LP | $82.25K | 42.98% | 2026-03-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $74.22K | 38.79% | 2026-03-31 |
| 3 | Persistent Asset Partners Ltd | $26.86K | 14.03% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $8.02K | 4.19% | 2026-03-31 |
Insider Activity
Latest: 2026-07-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Other (J) | −76,000 | — | EDGAR | |
| 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Other (J) | −66,500 | — | EDGAR | |
| 2026-06-15 | Lynn Seely | President and CEO | Sell (S) | −388 | $18.91 | -$7.3K | EDGAR |
| 2026-06-15 | Stephen J. Hill | Chief Operating Officer | Sell (S) | −89 | $18.92 | -$1.7K | EDGAR |
| 2026-06-15 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell (S) | −217 | $18.91 | -$4.1K | EDGAR |
| 2026-06-15 | Gary K. Lee | Chief Scientific Officer | Sell (S) | −130 | $18.92 | -$2.5K | EDGAR |
| 2026-06-12 | Mark Bachleda | Director | Grant (A) | +9,250 opt | — | EDGAR | |
| 2026-06-12 | Richard Klausner | Director | Award (A) | — | — | EDGAR | |
| 2026-06-12 | OTIS W BRAWLEY | Director | Award (A) | — | — | EDGAR | |
| 2026-06-12 | ELIZABETH G NABEL | Director | Grant (A) | +9,250 opt | — | EDGAR | |
| 2026-06-12 | CATHY FRIEDMAN | Director | Award (A) | — | — | EDGAR | |
| 2026-06-12 | WILLIAM JL RIEFLIN | Director | Grant (A) | +9,250 opt | — | EDGAR | |
| 2026-06-12 | Sumant Ramachandra | Director | Award (A) | — | — | EDGAR | |
| 2026-06-11 | David Shook | Chief Medical Officer | Sell (S) | −1,977 | $12.64 | -$25.0K | EDGAR |
| 2026-03-16 | Smital Shah | Chief Fin. and Bus. Officer | Grant (A) | +140,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
20 insiders · @ $14.05
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | 2,857,500 | $40.15M | $0 | 2 | 2026-07-01 |
| 2 | GSK plc | 10%+ Owner | 1,512,659 | $21.25M | $0 | 1 | 2021-06-23 |
| 3 | ROBERT NELSEN | Director | 910,318 | $12.79M | $0 | 5 | 2024-06-17 |
| 4 | ARCH Venture Partners IX, L.P. | 10%+ Owner | 910,318 | $12.79M | $0 | 1 | 2021-06-23 |
| 5 | PAUL L BERNS | 10%+ Owner | 910,317 | $12.79M | $112.50M | 1 | 2026-03-09 |
| 6 | ARCH Venture Partners IX, LLC | 10%+ Owner | 910,317 | $12.79M | $62.50M | 1 | 2026-03-09 |
| 7 | KEITH CRANDELL | 10%+ Owner | 910,317 | $12.79M | $0 | 1 | 2025-07-29 |
| 8 | Hans Edgar Bishop | Director | 234,281 | $3.29M | $0 | 7 | 2024-06-17 |
| 9 | Richard Klausner | Director | 190,557 | $2.68M | -$108.4K | 10 | 2026-06-12 |
| 10 | Lynn Seely | President and CEO | 73,878 | $1.04M | -$177.1K | 13 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2023-08-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2023-08-15 | Klausner Richard | Director | 4,485 | $10.3K | 2023-08-15 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-08-15 | Klausner Richard | Director | 4,485 | $10.3K | 2023-08-15 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-08-15 | Klausner Richard | Director | 44,565 | $102.1K | 2023-08-15 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-08-15 | Klausner Richard | Director | 4,485 | $10.3K | 2023-08-15 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-07-17 | Klausner Richard | Officer, Director | 14,500 | $42.0K | 2023-07-13 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-07-17 | Klausner Richard | Officer, Director | 3,300 | $9.6K | 2023-07-13 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-07-17 | Klausner Richard | Officer, Director | 3,300 | $9.6K | 2023-07-13 | Raymond James & Associates, Inc. | — | EDGAR |
| 2023-07-17 | Klausner Richard | Officer, Director | 3,300 | $9.6K | 2023-07-13 | Raymond James & Associates, Inc. | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.1 |
| P/S Ratio | 9762.7 |
| EV/EBITDA | -1.2 |
| TTM Revenue | $0.0B |
| TTM Net Income | $-0.2B |
| TTM EPS | $-13.8 |
| ROE | -90.0% |